It takes less than a minute to create your secure account – you just need to tell us
a few details about yourself and create a password.
I can’t remember my password
Please click on the “Forgot my password” link in the login form and follow the
instructions.
I can’t remember the email address I registered my account with
Please email info@pharmacy-network.co.uk so we can check for you.
What learning content do you have?
Pharmacy Magazine contains a library of high-quality
educational e-learning modules, videos and articles to support your ongoing
learning.
Is the learning suitable for all pharmacy team members?
Yes, we have content suitable for all abilities, with topics covering business
management, clinical, practice and OTC. Our aim is to help you keep up to date and
develop your skills and knowledge to positively influence patient outcomes and customer
experiences.
Can I access the library on my mobile?
Yes, you can access all learning at work or at home on any mobile, PC or tablet
device
What’s the best way for me to find relevant content for my role?
There are three ways you can find relevant content. Firstly, the homepage will display
suggestions for you. If you are logged in, we can tailor the content to your particular
job role and topics of interest, as well as making it easy for you to see what’s
trending. Secondly, you can use the “search” function at the top of the website.
Finally, you can click on “explore” in the main menu and browse topics of interest to
you.
How long do modules take?
We have a range of modules and videos ranging from 2 minutes up to 15 minutes. There
is something for everyone, even if you are short on time.
Can I save content for later?
Yes. If you see a piece of learning you would like to take, but haven’t got time right
now, you can “Bookmark” it for later. Please note you need to have a registered account
and be logged in to access this feature.
Can I record my learning outcomes?
Yes, logged in members can record their learning outcomes on any piece of content and
save them in their learning log. Pharmacists and technicians can do this using recording
templates in line with GPhC requirements.
How do I get a learning log?
You have to register an account on Pharmacy Magazine and login
to access your personal, secure learning log.
What does my learning log do?
It documents all the learning you have recorded, including completed learning, learning
in progress and bookmarked learning you have saved to do later.
If I’m a pharmacist or pharmacy technician, can the log help me fulfil the GPhC’s
revalidation requirements?
Yes, pharmacists and pharmacy technicians also have the ability to record and add their
own revalidation entries to their learning log in line with GPhC requirements.
If I’m a member of more than one website on The Pharmacy Magazine,
can I access all my learning in my learning log even if I’ve recorded it on different
websites?
Yes, if you record learning on more than one website, it will be displayed in your
learning log which is shared across all the accounts you have registered with The
Pharmacy Magazine.
How do I view/print a certificate of my learning?
Certificates are available at the end of every module, after the assessment questions.
They are also accessible via the learning log.
How do I change my personal details, email address and password?
Login and click on “Settings” in your member menu and click on the relevant links to
change any of your details. All saved changes take immediate effect.
If I leave the industry and want to delete my account, can I do so?
Yes absolutely. You are able to delete your account at any time but please be aware that
by doing so you will also delete any historical learning records you have in your
learning log.
If I have a query or I’m stuck, how can I get help?
You will need to have registered an account to get help. Logged in members can click on
the “Helpdesk” link in their Settings and submit a Helpdesk ticket. We endeavour to
respond to new Helpdesk tickets within 24 hours during office hours (9pm to 5pm Mon to
Fri)
How can I check on your Terms of Service, Privacy Policy and Cookie Policy?
You can click on the relevant links in the footer of the website. If there are any
proposed changes to any of our Policies, we will email registered members in
advance.
Is Pharmacy Magazine GDPR compliant?
Yes we are and we take your privacy and the security of your data extremely
seriously. Please read the Privacy Policy for further details. Logged in members can
click on the “My data” link in “Settings” to download a copy of all the personal
data we currently hold on you.
Who is the company that owns and operates Pharmacy Magazine?
Communications International Group Limited (CIG), the largest, most experienced publisher
in the UK pharmacy sector. CIG is one of the UK’s leading provider of sector-specific news and
training, publishing 15 healthcare and beauty titles including Pharmacy Magazine,
Training Matters, P3Pharmacy, Independent Community Pharmacist and Beauty Magazine. Over
the years the company has built an enviable reputation in pharmacy, journalism,
education, training, regulatory, awards and conferences, that today amounts to more than
350 years of healthcare industry experience.
How do I sign out?
Click on the Sign Out link that can be found at the top of the website, in you member
menu.
Mark Greener reports on nail disorders with GLP-1 receptor agonists, a urine test for bladder cancer, night-time light and heart health, and lamotrigine for migraine aura
GLP-1RAs may increase the risk of nail disorders, according to a multi-national, cross-sectional study presented during the European Academy of Dermatology and Venereology Congress in Vienna.
Researchers in France, the US, Brazil and Mexico compared 575 people taking GLP-1RAs with 1,329 controls who had never taken these drugs. All participants had type 2 diabetes, obesity or both. Patients received GLP-1RAs for an average of 18.5 months.
Overall, 66.3% of GLP-1RA users and 52.8% of controls experienced at least one nail disorder. For example, nail detachment was seven times more common among GLP-1RA users than controls (39.3% and 8.7% respectively; odds ratio [OR] 6.84).
Dyschromia was four times more common among GLP-1RA users than controls (45.6% and 17.0% respectively; OR 4.09). Onycholysis (OR 2.29), ridges/grooves (OR 1.89) and fragility (OR 1.34) were also more common among those receiving GLP-1RAs.
The differences remained significant when the analysis included only patients who lost weight, so weight loss alone does not account for the increased nail problems. Adjusting for dermatological conditions and nutritional deficiencies reduced the strength of some associations. However, nail detachment and discolouration were still two to three times more common among GLP-1RA users than controls.
“Until now, nail changes associated with GLP-1 therapies had essentially been anecdotal,” says study author Charles Taïeb, European Market Maintenance Assessment, Paris, France.
“Our findings show a clear association, but they also underline an important point: not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself.”
Urine test for bladder cancer
Bladder cancer is the 11th most common malignancy and the ninth most common cause of cancer death in the UK. Now US researchers report that a urine test can diagnose bladder cancer more accurately than current methods.
Increasingly, cancer specialists use small pieces of DNA released into the blood (circulating tumour DNA) as cancer cells die to diagnose malignancies, and guide and monitor treatment.
However, normal cells lining the bladder often accumulate mutations that overlap with those in the cancer. DNA tests can mistake these ‘bystander mutations’ for malignancy. So, the tumour and normal tissue are sequenced to identify which mutations to track.
The new test measures circulating cell-free RNA (cfRNA), which reflects overall gene activity. “You’re looking for a biological signature of disease, not an exact likeness, and urine is a non-invasive way to accurately detect and track bladder cancer,” says Professor Ash Alizadeh, Stanford University. Researchers tested 683 urine samples from patients with cancer and controls. The test showed 95% sensitivity and 90% specificity for detecting localised bladder cancer.
In other words, urine cfRNA correctly identified 95% of people with localised bladder cancer and correctly cleared 90% of those without. It outperformed standard urine cytology and a DNA-based urine test.
Urine cfRNA also identified residual cancer after surgery and Bacillus Calmette-Guérin (BCG) immunotherapy, and revealed a pattern of changes that identified people likely to respond to BCG.
Nocturnal light exposure is linked to cardiovascular disease (CVD) and potentially harmful changes in the heart’s structure and function, according to researchers who followed 73,286 UK Biobank participants for 8–10 years.
“This is the first study of its kind and it shows that exposure to higher levels of light at night-time is linked to cardiac remodelling,” says study leader Professor Lu Qi, Tulane University, New Orleans. An accompanying editorial concludes that darkness is “a vital sign, as essential to cardiovascular health as blood pressure control and clean air”.
People exposed to more than 3 lux of light during the night (a candle at one metre produces about 1 lux) were more likely to experience stroke (by 33%), heart failure (29%), CVD death (26%), myocardial infarction (24%) and atrial fibrillation (15%) than people with almost no night-time light exposure.
In addition, 11,071 people wore wrist light sensors for seven days and underwent magnetic resonance imaging three years later. Adjusting for confounders, night-time light above 3 lux was associated with thickening of the left ventricle and reduced flexing of the heart during heartbeats. The right ventricle and left atria also showed potentially harmful changes.
Shorter sleep duration accounted for 24–49% of the changes to the heart’s structure and function. The changes and the increased CVD risk were more marked as nocturnal light intensity rose.
“Our findings, together with evidence from other studies, suggest that reduction of night-time light exposure should be considered as one of the potential strategies for preventing heart disease by clinicians and policy makers,” Qi concludes.
Lamotrigine reduces the frequency of migraine aura by 80%, Swedish scientists report. There is no established treatment that specifically targets aura, and migraines with and without aura are often treated in a similar way, says study author Gürdal Sahin of Lund University.
The retrospective study included 81 patients, 67.9% of whom were women. Most (98.7%) reported visual aura, while 45.6% experienced sensory aura, 32.0% speech and/or language disturbances and 9.8% extreme photosensitivity.
Reaching the average maintenance dose of 149.6mg took a median of 11 months, and treatment lasted a median of 44 months.
Lamotrigine prophylaxis reduced the mean number of monthly aura days from 6.9 to 1.4, a 79.7% reduction. Overall, 85.2% of participants reported at least a 50% reduction in monthly aura days.
Twenty-nine (35.8%) patients experienced adverse events: 14 reported skin-related changes such as rash and hair loss, and 11 cognitive changes including dizziness and impaired concentration.
Five discontinued lamotrigine because of side-effects and one experienced visual hallucinations of insects.
The study authors are now proceeding with a randomised, double-blind, placebo-controlled trial of lamotrigine.